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ABSTRACT
The purpose of this study was to observe how the presence of peripheral arterial disease affects
the level of post-exercise blood lactate and post-recovery blood lactate during and following the
six-minute walk test (6MWT). The 6MWT was administered to 49 participants (33 classified as
Non-PAD and 16 classified as PAD) over the age of 50 with no uncontrolled cardiovascular or
metabolic diseases or a cardiovascular event in the previous 6 months. Results demonstrated that
no significant statistical difference exists between the presence of PAD and resting blood lactate
(F = 0.86, p = .36), post-exercise blood lactate (F= 0.48, p = .49), or post-recovery blood lactate
(F = 1.62, p = .21). Although the data failed to demonstrate statistical significant difference
between the presence of PAD and these variables, this could be due, in part, to the relatively mild
arterial occlusion seen in the population used in this study. Perhaps more severe cases of PAD
would yield significant differences between the two groups following the 6MWT.
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CHAPTER ONE
INTRODUCTION
Peripheral Arterial Disease (PAD) is a subset of cardiovascular disease affecting 12-20%
of adults over the age of 65 in the United States (Roger et al., 2012). PAD is the systemic buildup of plaque in the femoral artery of the leg(s) which leads to decreased blood flow to the
affected limb. It often goes unnoticed until symptoms of intermittent claudication (IC) are felt
and the individual’s functional capacity is decreased significantly. PAD is typically found in
adults over the age of 65 and symptoms can range from very mild to life threatening. When
compared to healthy controls, PAD patients have many physiological adaptations and
abnormalities due to different manifestations of the disease. These abnormalities can be seen as
changes in peripheral blood flow, skeletal muscle metabolic myopathies, rate of oxygen
desaturation, oxygen uptake kinetics, rate of metabolic intermediate build-up, and a surplus of
certain enzymes during exercise (Bhat, Hiatt, Hoppel, & Brass, 1999).
The prominent change with PAD is decreased blood flow to the limb with the occluded
vessel. This results in ischemia which implies an insufficient supply of oxygen, glucose, and
other important nutrients to the working muscle (Hlavova, Linhart, Prerovsky, Ganz, & Fronek,
1965). The other important impact of decreased blood flow is that there is less blood to clear
away the harmful metabolic waste of the working skeletal muscle. This causes an
uncharacteristically rapid build-up of different substrates in the muscle and in the blood which
can debilitate the muscle’s ability to keep working (Robbins et al., 2011). The extent of vessel
occlusion determines the extent to which blood flow is diminished. This is easily measured by
the Ankle Brachial Index (ABI) and this number is indicative of PAD severity (e.g. the lower the
ABI, the greater the decrease in blood flow to the limb) (McDermott et al., 1999).
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The other physiological changes with PAD frequently go unnoticed because they occur at
the cellular level. The skeletal muscles in the affected limbs of PAD patients often have many
different metabolic abnormalities when compared to individuals without PAD. These
irregularities include atypical muscle mitochondrial enzyme expression (Lundgren, Dahllof,
Schersten, & Bylund-Fellenius, 1988), abnormal accumulation of oxidative metabolism
intermediates (i.e. lactate) (Hiatt, Wolfel, Regensteiner, & Brass, 1992), and slowed kinetic
response to exercise (Kemp et al., 1993). These changes in the skeletal muscles of patients with
PAD are the cause of the more traditional symptoms that are generally associated with the
disease.
Symptoms of PAD are dependent on the extent of vessel involvement and collateral
circulation to the specific area. Traditional symptoms with PAD include IC, decreased functional
capacity, decreased exercise capacity, and an overall sedentary lifestyle (Hiatt, Regensteiner,
Wolfel, Carry, & Brass, 1996). Intermittent claudication, or ischemia-induced leg pain, is the
most noticeable of all symptoms but, like the others, it is the result of the metabolic dysfunction
of the skeletal muscle as well as the ischemia due to the occluded femoral artery. PAD is often
associated with a decreased quality of life (Liles, Kallen, Petersen, & Bush, 2006) and increased
risk of depression (Arseven, Guralnik, O’Brien, Liu, & McDermott, 2001) due to the functional
restrictions caused by the metabolic changes and abnormalities.
When evaluating exercise performance in patients with PAD, maximal walking time and
peak VO2 can be used to define maximal performance. Oxygen consumption is an objective
performance measure that is used to define functional capacity in all individuals. In healthy
individuals, a plateau in VO2 signifies maximal exercise. However, in individuals who have
impaired exercise performance due to cardiovascular disease, peak VO2 can be used because it

3
defines the highest VO2 achieved during exercise, regardless of whether a plateau was reached or
not. Because of this, peak VO2 has been shown to be more closely correlated than VO2 max to
the degree of functional impairment in individuals with cardiovascular disease. In individuals
both with and without PAD, peak VO2 is correlated with maximal walking time (Hiatt, Nawaz,
Regensteiner, & Hossack, 1988). However, skeletal muscle ischemia limits exercise performance
in PAD patients and maximal heart rate, VO2, and the respiratory exchange ratio in this
population are lower than age-matched healthy individuals (Eldridge & Hossack, 1987). These
observations would suggest that, during the 6MWT, performance variables such as heart rate
would not be elevated to the same degree in PAD participants when compared to non-PAD
participants due to skeletal muscle ischemic limitations.
A common mode to measure functional capacity in this population is the 6MWT. The
6MWT was developed for clinical settings by the American Thoracic Society Pulmonary
Function Standards Committee and was used originally for patients with asthma but has since
been adopted as a measure of functional ability in many diseased populations (Enright, 2003). It
has become a staple in the cardiovascular community, particularly for patients with PAD. Basic
standards for completing this test require an individual to walk as far as they can in the allotted
six minutes. The primary outcome variable is total distance covered (Enright & Sherrill, 1998).
This test is a commonly accepted and often required measure of functional ability in individuals
with diagnosed PAD and is used to measure both the extent of functional loss as well as the
extent of functional improvements from PAD treatment and exercise therapy. Typically,
individuals with PAD exhibit significantly lower scores than healthy individuals in the 6MWT
due to traditional PAD symptoms and restraints such as IC, decreased functional capacity, and
decreased exercise capacity. A normal distance for healthy adults over the age of 50 to score
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during the 6MWT is between 450-700 yards (Chetta et al., 2006). A typical distance for adults
with PAD is between 250-400 yards (Regensteiner et al., 1993). This lower score is also
associated with the lower functional and exercise capacities observed in individuals affected by
PAD (Gardner, Katzel, Sorkin, & Goldberg, 1998).
Hemoglobin saturation refers to the degree to which hemoglobin is loaded with oxygen
molecules. Each hemoglobin molecule has the capacity to bind with up to four oxygen molecules
and carry them to the working muscle. If all four oxygen molecules are attached to the
hemoglobin, the hemoglobin is fully saturated (Bauer, Regensteiner, Brass, & Hiatt, 1999).
Measuring hemoglobin saturation is a safety tool often utilized to ensure that an individual is
supplying an adequate amount of oxygen to their working muscles. Hemoglobin saturation can
be measured easily and non-invasively by a pulse oximeter. In a healthy individual, a
hemoglobin saturation of <90% is a contraindication to continue exercising. However, because
this study included a diseased population group, this value was placed at a more conservative
<92% cut off. In accordance with these extra precautions, hemoglobin saturation values were
recorded to ensure that the participants maintained a healthy and sufficient amount of oxygen to
their muscles throughout the test.
Statement of Problem
It is known that individuals with peripheral arterial disease have elevated lactate levels at
rest and after exercise (Barker, Green, Green, & Walker, 2004). However, these measures have
not been taken during the 6MWT to determine if these abnormalities occur in this short time
span and to what degree they occur, if they do. The rate of lactate clearing following the 6MWT
is also unknown in this population. This thesis sought to determine the level of post-exercise
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blood lactate and the level of post-recovery blood lactate in individuals with PAD when
compared with a control population during the 6MWT.
Purpose
The purpose of this study was to observe how the presence of peripheral arterial disease
affects the level of post-exercise blood lactate and post-recovery level during and following the
6MWT. Blood lactate levels were measured before, immediately following the 6MWT, and postrecovery in order to define differences between PAD and Non-PAD populations.
Hypotheses
Null:
1. There will be no difference in resting blood lactate levels between PAD patients and
healthy controls
2. There will be no difference in post-exercise blood lactate levels between PAD patients
and healthy controls during the 6MWT
3. There will be no difference in post-recovery blood lactate levels between PAD patients
and healthy controls post the 6MWT
Research:
1. PAD patients will have a higher resting blood lactate level when compared to healthy
controls
2. PAD patients will have a higher level of blood lactate post-exercise during the 6MWT
when compared to healthy controls
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3. PAD patients will have a higher level of blood lactate post-recovery following the
6MWT when compared to healthy controls
Operational Definitions
Ischemia is defined as the restriction of blood to a tissue which infers a shortage of
oxygen and other nutrients necessary for tissue functioning (Hlavova et al., 1965).
Intermittent Claudication is defined as severe leg pain during exertion. This pain is
generally felt in the calf muscles and is described as severe cramping or tightness. This pain
slowly builds with exercise until severe enough that the individual has to call an end to all
physical activity. The pain subsides at rest. Intermittent claudication is associated with a 50%
reduction in walking performance and is the primary external cause of decreased functional
capacity in patients with Peripheral Arterial Disease (Hou et al., 2002).
The Ankle-Brachial Index is a noninvasive test used to define the presence and severity of
PAD. ABI compares the blood pressure in the ankle to the blood pressure in the arm. A low ABI
can indicate narrowing or blocking of the arteries in the legs (McDermott et al., 1999). Below is
the general classification of blockage severities:
Healthy Adults= 0.91-1.30
Blockage= 0.40-0.90
Severe Blockage= less than 0.40
In accordance, Peripheral Arterial Disease was defined by an ABI of less than or equal
to 0.90 when being classified as PAD positive.
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The Six Minute Walk Test is a walking test to determine fitness level in unhealthy
populations. The American Thoracic Society has determined that this test is safe, easy to
administer, well tolerated, and reflects the daily activities of the target population. Primarily, this
test measures overall distance covered by an individual in six minutes (Enright, 2003). This test
is an often used measure in the PAD population because of the disease-induced limitations and
intermittent claudication experienced by patients.
Post-exercise lactate in this study was determined by subtracting resting blood lactate
from blood lactate taken immediately following the 6MWT.
Post-recovery ;actate was determined by subtracting post-exercise blood lactate from the
blood lactate value taken following 20 minutes of rest after the 6MWT.
Functional capacity is a term used to describe an individual’s ability to perform normal
daily tasks. This does not include exercise capacity; it refers strictly to activities of daily living.
Exercise capacity is a term used to describe an individual’s ability to exercise at any
intensity for a prescribed period of time.
Assumptions
1. Based on an overview of the literature, it is assumed that lactate will accumulate in the
blood during the 6MWT in both PAD patients and healthy controls.
2. It is assumed that during the 6MWT, participants are giving 100% effort and performing
the test to volitional exhaustion or the conclusion of six minutes.
3. It is assumed that participant’s blood lactate will not be elevated due to any other cause
apart from walking.
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4. It is assumed that all participants will be able to perform and complete the 6MWT due to
the self-selected intensity.
Limitations
There are several limitations that presented themselves in this study. First, the severity of
the artery occlusion in PAD patients was a limitation due to varying severities playing a role in
overall post-exercise and post-recovery blood lactate. Second, the inability to control for an
entirely healthy population versus a strictly PAD population was a limitation because almost all
participants had other comorbidities that could have affected results. Third, all of the different
medications being taken by each individual for different conditions and diseases was a limitation
because the physiological effects of these medications was not considered. And last, inability to
force individuals into high intensity exercise from a more low-to-moderate state was a limitation
because it changed the 6MWT from a maximal test to a timed, moderate-intensity test and this,
in turn, could have affected the overall rate and amount of post-exercise and post-recovery blood
lactate.
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CHAPTER TWO
REVIEW OF LITERATURE
Peripheral Arterial Disease (PAD) is systemic atherosclerosis that typically occurs in the
lower extremity arteries. Having PAD puts an individual at an increased risk of stroke,
myocardial infarction, and cardiovascular death when compared to healthy individuals (Liles et
al., 2006). It is estimated that between 10-12 million people in the United States have PAD,
however this number may be underestimated due to those individuals that remain undiagnosed
because they are currently asymptomatic. There are many treatment options for individuals with
PAD including pharmacotherapy, risk factor reduction, and exercise interventions. These
treatments, when used effectively, can decrease the severity of the atherosclerosis and increase
the patient’s overall quality of life. It is estimated that approximately 70% of individuals
diagnosed with PAD remain stable or improve if proper medical advice and treatments are
utilized (Liles et al., 2006).
Generally, atherosclerosis, including that manifested in the periphery, is a dangerous
inflammatory disorder that may be initiated by several lifestyle factors such as diabetes, smoking,
hypertension, and dyslipidemia. One of the most important factors responsible for atherosclerosis
is low density lipoprotein (LDL) levels in the blood. LDLs enter the artery wall from the plasma.
Once the plasma level of LDLs exceeds the threshold, LDLs enter the sub-endothelial space
faster than they can be removed and accumulate. These accumulated LDLs then become
oxidized and stimulate endothelial cells to express a protein, monocyte chemotactic protein-1
(MCP-1), that causes a release of monocytes from the blood into the artery wall. The modified
LDLs then convert monocytes into macrophages and then undergo an unregulated uptake of
oxidized LDLs until they rupture, causing fatty streaks on the endothelium. Macrophages express
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several cytokines that activate endothelial cells to express adhesion molecules. These proteins
bind the plasma monocytes to the endothelium and then are attracted into the artery wall by
MCP-1. The entry of LDLs into the endothelium begins a cycle that commences atherosclerosis
and can also lead to its progression (Deedwania et al., 2006). In patients with PAD, this plaque
buildup occurs in the femoral artery and is known to cause many issues including inhibited blood
flow, ischemia, claudication, and other pathophysiological adaptations in the skeletal muscles
and cells.
PAD is associated with two primary consequences: the first is a significant decrease in
quality of life and overall well-being due to intermittent ischemic pain of the lower limbs. This is
typically exemplified in an overall sedentary lifestyle and possible depression. The second
consequence is a significantly higher likelihood of cardiovascular morbidity and mortality (Olin
& Sealove, 2010). This risk of cardiovascular mortality has been found to be similar between
diagnosed PAD patients experiencing claudication pain and patients that are asymptomatic.
Symptoms of PAD are dependent on the extent of vessel involvement and collateral
circulation to the specific area. The primary symptom of PAD is claudication which is an
impairment in an individual’s walking ability due to pain, discomfort, tiredness, cramping, or
aching in the legs. Claudication symptoms generally grow more severe as exertion and/or
duration increases. This leg pain can range from intermittent claudication during exertion to
claudication at rest and even to gangrene (Oka, Szuba, Giacomini, & Cooke, 2003). Patients with
PAD have significant functional impairments and physical restrictions due to claudication
symptoms.
Quality of life (QoL) is significantly associated with PAD severity. PAD affects the
individual’s perceived QoL in both physical and psychosocial functioning. Decreases in physical
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functioning can lead to depression, loneliness, emotional distress, and social role limitations
(Liles et al., 2006). An individual’s psychosocial functioning decreases as a result of the
knowledge that they are living with a chronic disease, the label of being a “PAD patient,” and the
perceived loss of control over their body and life (Liles et al., 2006). In patients with PAD versus
patients with cardiovascular disease (CVD), Health Related Quality of Life (HRQoL) was found
to decrease similarly despite the specific disease diagnosis. Both populations also experienced a
decrease in physical function although PAD patient’s losses were attributed to leg-related
symptoms while CVD patient’s losses were attributed to cardiac symptoms (Regensteiner et al.,
2008).
Risk Factors for PAD
There are several discrepancies in the literature about which demographics are at a higher
risk for being diagnosed with PAD. The Rotterdam study sought to determine if a relationship
existed between age and PAD prevalence. They sampled a group of 7715 subjects over 55 years
old living in Rotterdam, the Netherlands. Of these participants, 19.1% were classified as having
peripheral arterial disease. The Rotterdam study found that the prevalence of PAD and
intermittent claudication symptoms increases drastically with age. Men who were 55 years old
were at 6.6% risk for developing PAD but when looking men who were 85 years old, there was a
sharp increase to 52.0%. Women in these corresponding age groups saw increases in PAD risk
grow from 9.5% to 59.6% (Meijer et al., 1998). This data showed that the risk for developing
PAD increased exponentially with age.
Several studies have also been conducted to determine if gender contributes to an
individual’s risk to develop PAD. These results are inconsistent between studies. The Rotterdam
study showed that the prevalence of PAD was higher among women than men (20.5% vs 16.0%)
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but the presence of intermittent claudication in individuals with PAD was higher among men
when compared to women (8.7% vs 4.9%) (Meijer et al., 1998). Conversely, a study done with
403 patients showed that the prevalence of PAD in women was 15.9% compared with a higher
17.4% in men. They also reported that physical functioning in patients with PAD was
significantly lower in women when compared with men (Collins, Suarez-Almazor, Bush, &
Peterson, 2006). Physical functioning differences between genders could be seen when
evaluating individual’s ability to perform daily tasks, functional ability, and overall physical
ability; this discrepancy between genders could be attributed to the increased claudication
symptoms experienced by women (Meijer et al., 1998). Other researchers looked at the effect of
gender on PAD patients’ overall quality of life. Oka et al. (2003) compared the perception of
PAD between genders and respective quality of life. Results from this study showed that PAD
has a much greater negative impact on women than men in regards to health related quality of
life (HRQoL), physical functioning, and emotional distress. Similar results were also found by
McDermott et al. (2003). She associated women’s greater decrease in physical functioning with
the poorer leg strength generally found in women with PAD when compared to men with PAD.
This decreased physical functioning in women plays a role in their overall perception of their
quality of life and therefore, greater functional decreases in women could be the reason that
women express lower HRQoL scores. The irregularity in the results when examining gender as a
risk factor for developing PAD shows that gender is not a strong risk factor for the development
of PAD and therefore prevention and treatment methods for this disease should be focused on
both genders equally.
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Comorbidities
Research has found that individuals with PAD are at an increased risk of cardiovascular
morbidity and mortality compared to individuals without PAD (Meijer et al., 1998). This
increased risk is seen, in part, because of the high degree of overlap between the
pathophysiology of peripheral arterial disease and cardiovascular disease. Schainfield (2001)
found that CVD can be detected in as many as 90% of individuals with present intermittent
claudication. In addition, diabetes and impaired glucose tolerance have a high correlation with
the development and progression of PAD. Among a group of 7715 individuals with known PAD,
approximately 10% had also been diagnosed with diabetes mellitus (Meijer, 1998). Because of
the high association with atherosclerotic diseases and cholesterol levels, specifically elevated
LDLs, lipid abnormalities are also a very prevalent comorbidity with PAD. In individuals with
PAD who are also hypertensive, the risk of claudication can increase 2-3-fold (Schainfield,
2001). Meijer and colleagues reported that up to 33% of patients with PAD were also
hypertensive (1998). Other studies have identified increased fibrinogen and blood viscosity as
important risk factors in the development of PAD (Schainfield, 2001). Robeer and colleagues
(1998) examined 460 PAD patients and determined the prevalence of cancer, pulmonary disease,
and history of coronary revascularization. They found that the percent of individuals with both
conditions were 16.0%, 32.5%, and 35.7% respectively. These findings show that the presence of
PAD in individuals is often coupled with the presence of other comorbidities and medical
complications and needs to be treated in conjunction with these other conditions.
Femoral Vessel Occlusion
The femoral artery and its branches supply blood flow to the entire leg. When individuals
age, there is a decrease in leg blood flow and femoral artery vascular conductance when
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compared with younger adults; this decrease is seen even in trained individuals (Proctor et al.,
1998). Results from a study examining these age-related, hemodynamic changes in trained older
men found that the fit older men had a 25% decrease in leg blood flow at different exercise
intensities when compared to trained younger men (Proctor et al., 1998). The study also looked
at leg vascular conductance which is calculated as limb blood flow divided by the mean arterial
pressure (Proctor, Le, & Ridout, 2005). Vascular conductance was shown to be, on average, 2630% lower in older versus younger men. Lastly, Proctor et al. (1998) examined oxygen
saturation in the femoral artery and found that hemoglobin saturation is lower in healthy older
men versus the healthy younger men. These studies have shown that vascular conductance, blood
flow, and oxygen saturation all decrease with age in a healthy population. In a diseased
population, these numbers decrease even more drastically. With vessel occlusion, blood flow
decreases to a greater degree along with vessel conductance, compliance, and oxygen kinetics.
Blood flow in individuals with claudication symptoms was found to decrease by almost 50%
when compared to healthy controls during exercise (Pernow, Saltin, Wahren, Cronestrand, &
Ekestrom, 1975). This decrease in blood flow as a result of femoral vessel occlusion has
significant implications on skeletal muscle contractility as well as metabolite production in
individuals with peripheral arterial disease.
Blood Flow
Blood flow is known to be decreased in individuals with atherosclerotic vessels. Hlavova,
Linhart, Prerovsky, Ganz, and Fronek (1965) compared differences in leg blood flow at rest,
during exercise, and after exercise in PAD patients compared to healthy controls. They found
that resting blood flow did not significantly differ amongst the groups; however, blood flow
during exercise was significantly lower in the PAD patients versus the control subjects. Pernow
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et al. (1975) found that common resting femoral artery blood flow was 0.53 liters/min in healthy
adults compared to 0.29 liters/min in adults with claudication symptoms. When exercising, blood
flow in the normal adults increased by 2.23 liters/min while the claudication group’s blood flow
only increased by 1.11 liters/min. This suggests that in individuals with severe femoral vessel
occlusion, such as in PAD patients, blood flow during exercise is dramatically compromised
which can cause many functional complications which inhibit performance and functional ability.
Dilation of larger peripheral arteries has been shown to occur in response to increased
blood flow through that vessel in a healthy adult; this phenomena is called flow–mediated
dilation. When blood flow is increased in a vessel, an increase in sheer stress occurs which
triggers the release of nitric oxide (NO), a potent vasodilator. This vasodilation of the vessel
provides a greater area for the blood to travel. However, in atherosclerotic vessels, arterial
compliance is significantly decreased and the body’s flow-mediated dilation response is impaired
(Cox et al., 1989). This is a functional mechanism that can partially explain why an individual
with atherosclerotic vessels does not have the proper blood flow response to exercise. This data
can also be used to understand why an individual with PAD’s ABI decreases with exercise.
Microcirculation, or capillary density, has also been the target of several studies when
investigating the decreased functional capacity in PAD patients. The proposed relationship
between capillary density and walking capacity represents the amount of blood that is reaching
the working muscles. Robbins et al. (2011) examined this phenomena and found that capillary
density was 18% lower in PAD patients when compared to healthy controls. This decrease in
capillary density was also correlated to an individual’s functional impairment as shown by a
lower peak VO2, peak walking time, and claudication onset time when compared to healthy
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controls. These findings suggest that adaptations in microcirculation may play a role in the
decreased functional capacity associated with PAD.
Ankle-Brachial Index
The Ankle-Brachial Index (ABI) is the primary method used to diagnose PAD as well as
determine the severity of the vessel occlusion and ischemia. ABI is a non-invasive screening tool
that can easily identify the presence of PAD. ABI measurement is a number expressing the
systolic blood pressure in the ankle over the blood pressure in the brachial artery. If there is a
large discrepancy in the blood pressures, that is representative of femoral vessel occlusion and
ischemia in the affected limb. PAD is typically defined as an ABI of less than or equal to 0.90
(McDermott et al., 1999). This shows that blood flow in the lower limbs compared to the upper
limbs is drastically altered by an occluded vessel. The ABI has a sensitivity of 79% to 95% and a
specificity of 95% to 100% (Olin et al., 2010). An ABI of less than or equal to 0.90 is considered
PAD even though leg symptoms of claudication might not always be present. A high ABI has
been shown to be correlated with a loss in functional ability, a decreased walking distance, a
slower walking speed, and an increased prevalence of claudication pain (McDermott et al., 1999).
Typically, an ABI of 0.80-0.90 is considered relatively mild PAD; an ABI of 0.50-0.70
represents more severe PAD and individuals with these values typically have claudication
symptoms and significant decreased functional capacity (Ouriel, 2001).
Intermittent Claudication
Approximately one third of individuals with PAD exhibit traditional claudication
symptoms which are characterized by pain in one or both legs upon exertion, primarily in the
calves, that is not relieved until the activity is stopped (Hiatt, 2004). Claudication symptoms
progress in severity as time goes on; 5% of individuals with claudication symptoms undergo an
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amputation of the claudicating limb within five years. Even in individuals without traditional
claudication symptoms, atypical leg pain remains common and can affect ambulatory activity
and an individual’s overall quality of life (McDermott et al., 1999). Claudication symptoms are
the primary inhibitor of physical activity in patients with PAD and the presence of claudication is
directly correlated to the individual’s functional capacity. Exercise induces claudication
symptoms acutely but can chronically improve them by inspiring the formation of collateral
vessels, improving microcirculation and endothelial function, attenuating inflammatory
responses, and improving walking economy (Stewart, Hiatt, Regensteiner, & Hirsch, 2002).
Regensteiner and colleagues (1996) performed a 24-week walking exercise intervention study
for individuals with PAD and claudication symptoms. They found that with the implementation
of the exercise program, claudication severity was decreased by 29%. Claudication symptoms
are often determined by using a claudication scale as a guide for describing claudication pain
(Appendix 1). Claudication pain is a detrimental symptom of PAD and drastically decreases an
individual’s functional capacity and ability to perform physical activity.
Post-Exercise Lactate
Lactate is a byproduct of glycolysis formed through the reduction of pyruvate. The
conversion of pyruvate to lactate is driven by the enzyme lactate dehydrogenase (LDH). When
enough oxygen is provided to the working muscle, pyruvate is oxidized via pyruvate
dehydrogenase (PDH) and converted to acetyl-CoA to be used in the Citrus Acid Cycle. If PDH
is inhibited, as in the anaerobic milieu, pyruvate will be converted to lactate. Thus, in a hypoxic
state, lactate accumulates quickly (McNelis et al., 2001). It is important to note, however, that
lactic acid is constantly being produced in the body, not just at extreme exercise levels. At
resting states, a basal level of about 0.8-1.2 mM/minute of lactate is constantly circling in the
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blood (Mazzeo, Brooks, Schoeller, & Budinger, 1986; Hultman & Sahlin, 1980). The body
maintains this basal level by balancing the entry and removal of lactate from the blood; this is
called lactate turnover rate. Therefore, when lactate levels rise above basal values, it means that
entry is exceeding removal (Billat, 1996). Many studies have shown that lactate turnover rates
are higher in trained vs. untrained individuals (Hurley et al., 1984; Seip, Snead, Pierce, Stein, &
Weltman, 1991) and in young adults vs. older adults (Strandell, 1964). With decreased blood
flow both to and from the working muscle, as with PAD, lactate accumulation can occur at a
much higher rate and rises above basal level more quickly.
Adenosine triphosphate (ATP) is the energy source needed to initiate muscle contraction.
This is produced through different metabolic processes throughout the body. Primarily, ATP
production occurs when a glucose molecule is broken down through a process called glycolysis.
Glycolysis is the catabolism of glucose from its normal form to two pyruvate molecules via
many different steps that are driven by different enzymes. This process does not require oxygen
but results in a net four ATP molecules. Once pyruvate is formed, it then travels into the
mitochondria of the skeletal muscle where it is converted to Acetyl CoA and then enters the
Citrus Acid Cycle where many more ATP molecules are produced. However, when oxygen is
limited by respiration or ischemia, the process for the production of ATP is altered.
There are two primary types of exercise based on the two different metabolic states that
an individual is in: these are anaerobic metabolism and aerobic metabolism. Aerobic metabolism
typically occurs during submaximal work or long endurance activities where oxygen is available
and able to be delivered to the working muscle as needed. As previously described, when oxygen
is available, aerobic metabolism can occur by means of glycolysis with an end product of
pyruvate which is converted to Acetyl CoA and used in the Citrus Acid Cycle to produce energy.
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Alternately, anaerobic metabolism typically occurs in sprints or in maximal work where oxygen
is not available to be delivered to the working muscle at the amount that is required to sustain
work. When there is a lack of oxygen delivered to the working muscle, other mechanisms are
relied on to provide energy to the body such as anaerobic glycolysis or the use of high energy
phosphates like ATP or creatine phosphate (CP). During anaerobic glycolysis, pyruvate is
formed and then converted to lactic acid via lactate dehydrogenase (Guyton & Hall, 2000). This
lactic acid production is due to the fact that activation of glycolysis is occurring more rapidly
than the activation of oxidative phosphorylation. This results in an elevated net lactic acid
production. Elevated post-exercise lactate levels can be attributed to increases in power rather
than an insufficient oxygen supply because lactate accumulates as a result of the increase in the
activation of glycolysis (Billat, 1996). Lactate production is believed to be due to a “mass-action
effect” of high amounts of pyruvate production exceeding its rate of oxidation (Heighenhauser &
Parolin, 1999). The conversion to lactic acid prevents severe acidosis in the cell that would occur
from the excess of pyruvate and hydrogen atoms that are the end products of anaerobic
glycolysis. With the build up of either of these two substrates, the glycolytic process would halt
and the formation of ATP would be ceased. However, when in excess, these two end products
interact with each other to form lactic acid. This allows for the body to keep functioning during a
hypoxic state longer than it would be able to without this process. When oxygen is introduced
back into the system after an anaerobic state, lactate is reconverted to pyruvic acid where it can
then be converted to acetyl coA and enter the Citrus Acid Cycle to efficiently produce ATP
(Guyton & Hall, 2000). This is an important factor in individuals with decreased blood flow, as
seen in PAD, because there is an inadequate supply of oxygen to meet the demand of the
working muscle and the ensuing metabolic processes are often altered and pyruvate and
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hydrogen atoms interact to form lactic acid. This occurs at a higher rate when an inadequate
supply of oxygen forces the muscle into anaerobic metabolism in order to maintain the muscle’s
ability to contract.
In general, lactate levels are elevated during exercise. This can be attributed to many
different factors. Contracting skeletal muscle stimulates glycogenolysis and lactate production.
Also, during exercise, there are hormone-induced increases in glycogenolysis and glycolysis
which contribute to lactate production and therefore accumulation. Lastly, with exercise there is
a shunting of blood from lactate-removing, gluconeogenic tissues to lactate-producing glycolytic
tissues. This redistribution of blood flow causes blood lactate to rise during exercise (Brooks,
Fahey, & White, 1996). Depending on the exercise intensity, lactate begins accumulating above
resting levels within 15seconds-5 minutes or as heart rate exceeds 120 beats/minute in healthy
adults (Margaria, Oliva, Prampero, & Ceretelli, 1969). It is generally recognized that at work
rates exceeding 70% of VO2max, blood lactate levels systemically increase (Tanaka & Matsuura,
1984). At rest, pyruvate production matches pyruvate oxidation and so lactate is stable. However,
beginning in exercise around 60% of VO2max, pyruvate production begins to exceed pyruvate
oxidation and some pyruvate is converted to lactic acid via LDH (Heighenhauser & Parolin,
1999). Increasing blood lactate levels indicate that lactate production exceeds lactate catabolism.
Several factors contribute to blood lactate levels in an individual such as age, training level, and
mitochondrial deficiencies and diseases (i.e. PAD). These findings suggest that an increased
level of blood lactate above basal level could be expected during short duration, high intensity
activities, such as the six-minute walk test (6MWT), that require near-maximal effort.
Blood lactate levels represent overall lactate accumulation versus overall lactate
production. However, this blood lactate measurement is proportional to the net lactate
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accumulation in the whole body. Blood lactate measurements approximate the equilibrium
between lactate production rate and elimination rate as determined by many different
physiological modulators such as glycolysis kinetics, the activity of LDH, and mitochondrial
respiration. Blood lactate levels compared with skeletal muscle lactate levels have been found to
be different in humans. Lactate concentration in the blood is lower than in the working muscle.
This is because the process of lactate transport from the muscle into the blood is a relatively slow
process. This process is thought to be slow to protect the blood from acidosis (Sachs & Sachs,
1937). The increase in blood lactate as exercise progresses occurs due to the transport of lactate
from the muscle. Skeletal muscle lactate accumulates with repeated contractions and then is
released into the blood. Jorfeldt, Julin-Dannfelt, and Karlsson (1978) found that the release of
lactate from working skeletal muscle increased linearly with the amount of muscle lactate
content produced during a cycling protocol. This shows that blood lactate can be used as a
measure of overall lactate accumulation in an exercising individual due to its correlation to the
amount of lactate actually produced in the working muscle.
In PAD patients, oxidative metabolism kinetics during exercise are altered. In healthy
adults, the skeletal muscles rapidly use oxygen as exercise begins and these increases in oxygen
utilization by the muscle can be measured as changes in oxygen consumption (Barker et al.,
2004). By using nuclear magnetic resonance spectroscopy, Pipinos et al. (2000) further showed
that metabolic kinetics are slowed at the muscular level in PAD patients. Slowed oxygen kinetics
with PAD implies that the working muscle is unable to utilize oxygen efficiently. At rest, this is
not a big factor for individuals with PAD. However, with exercise, oxygen demand increases but
there is a decreased oxygen delivery to the working muscle due to vessel occlusion and a
decreased ability of the muscle to utilize the oxygen that is supplied. If there was an inadequate
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supply of oxygen to a working muscle with intact muscle oxygen utilization, there would be a
rapid hemoglobin desaturation rate. However, if oxygen was being delivered at an adequate
amount to a muscle with impaired muscle oxygen utilization, then at the onset of exercise there
would be a delayed hemoglobin desaturation rate. When looking at the onset of exercise in PAD
patients, hemoglobin desaturation is slowed when compared with healthy controls which shows
that there is a defect in the utilization of oxygen in the muscle. This shows that PAD patients
have impaired oxidative metabolic kinetics (Brass, Hiatt, & Green, 2004).
In patients with PAD, post-exercise lactate is elevated higher over normal values at rest
and at very low workloads. The ischemia associated with PAD plays a role in this metabolite
build up, however, there are other physiological mechanisms behind this heightened lactate
accumulation in circulation. Barker et al. (2004) showed that regulation of PDH is altered in
PAD patients. This suggests that pyruvate was being moved from complete oxidation towards
lactate production. PAD patients are also considered to have an acquired metabolic defect due to
the relatively normal blood flow at rest followed by oxygen-supply discrepancies during exercise
which is generally followed by maintained post-exercise hyperemia. This ischemia-reperfusion
injury leads to increases in oxidative stress (Neumann et al., 1990). The exaggerated postexercise blood lactate levels in PAD patients can be attributed to this oxidative stress as well as
metabolic pathophysiology and decreases in blood flow.
Post-Recovery Lactate
Clearing lactate is an important component of lactate accumulation; if lactate is not
cleared out of the blood, levels become dangerous and negatively feed back and inhibit muscle
contraction. Because of this, lactate clearance is a very important mechanism. Sometimes, blood
lactate accumulates as a result of overproduction but it is also increased as a result of poor lactate
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clearance. Lactate clearance is an important factor in predicting mortality; prolonged lactate
clearance is associated with an increased mortality rate in post-surgery patients (McNelis et al.,
2001). Blood flow is a significant factor in lactate clearance implying that there could be drastic
impairments in lactate clearance rates in individuals with decreased blood flow due to occluded
vessels.
At rest, lactate is removed from the blood by the liver, kidneys, and the heart. It is
oxidized in these organs or used in the gluconeogenic pathway for glucose production (Hultman
& Sahlin, 1980). During exercise, blood lactate is transported from the blood back into the
working muscle where it is used as a substrate for oxidative metabolism (Hultman & Sahlin,
1980). This contributes to the lactate turnover rate. Mazzeo et al. (1986) studied blood lactate
disposal rates and found that the average disposal rate was 123.4 mg/kg/hour at rest. In different
cardiovascular disease populations, the rate of lactate clearance is reduced due to the alterations
in both blood flow and oxygen kinetics. Subsequently, the pathophysiology of cardiovascular
disease and its subsets often alters the oxidative muscle metabolism of the exercising peripheral
skeletal muscles which contributes to both the increased production and the inhibited clearance
of lactate in the blood (Engelen et al., 2000).
Hemoglobin Saturation
Hemoglobin saturation is beneficial in understanding the role of blood flow and how that
affects skeletal muscle metabolism with the slowed kinetics evident in PAD patients.
Hemoglobin saturation can be measured non-invasively by using pulse oximetry technology.
This lightweight device slips over an individual’s finger and determines pulse and percentage of
hemoglobin saturation. It works by shining light through a cuvette filled with a lysed red blood
cell solution. The concentration of hemoglobin is determined by measuring the incident and
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transmitted light intensity through the known dimensions of the cuvette (Tremper, 1989). By
placing the fingertip, which contains a pulsating capillary bed, between two-wavelength light
source and a detector, it is able to determine hemoglobin saturation. In a study testing the
reliability of pulse oximeters, Yelderman and New (1983) found that there was a correlation
coefficient of 0.98 between pulse oximeter results and a carbon dioxide-oximeter and saturation
valves. They did find however that pulse oximeters become less reliable when adequate finger
pulsation is lost in situations such as hypothermia, hypotension, or severe vasoconstriction. They
concluded that pulse oximeters can accurately measure arterial hemoglobin oxygen saturation
between 70-100%. Another variable found to possibly alter the reliability of pulse oximeters is
motion. Motion can disturb the processing of light absorbance and alter the readings. Barker and
Shah (1997) evaluated the effect of motion on the accuracy of pulse oximeter readings. They
found that motion does play a key role in their accuracy and needs to be controlled. When
intending to use pulse oximetry during the 6MWT, it is important to limit hand movement during
time of readings to decrease the chance of skewed results.
Six-Minute Walk Test
The Six-Minute Walk Test (6MWT) is a test originally developed for asthma patients by
the American Thoracic Society (Enright, 2003). Its original intent was to measure maximal
distance covered by an asthmatic individual in the allotted six minutes. Since then, the 6MWT
has been utilized in many different populations as a measure of functional fitness due to the
safety, the reproducibility, and the ease of administration of the test (Enright, 2003). The
cardiovascular society is one of the main fields outside the thoracic society to use the 6MWT as
a measure of functional fitness within cardiac rehab facilities.
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The primary variable measured in the 6MWT is the overall distance covered by the
individual. However, there are many secondary measures that can be taken as well. These
include measures of fatigue or dyspnea, or in the case of the cardiovascular society, angina or
claudication. Arterial oxygen saturation taken with a pulse oximeter is also a common measure
recorded during the 6MWT. Blood samples can also be used to measure the build up of different
enzymes and metabolites in the blood (Enright, 2003). The 6MWT evaluates the whole-body and
integrated responses of the cardiovascular, pulmonary, and muscular systems in addition to
measuring the functional capacity of an individual that translates into their ability to perform
activities of daily living. Gardner et al. (1998) examined the relationship between activities of
daily living and different ambulatory measurements in PAD patients with intermittent
claudication symptoms. Energy expenditure of physical activity was determined and compared to
6MWT distances and other ambulatory measures. It was found that a low ability to perform daily
activities was correlated strongly with a decrease in walking ability as measured in the 6MWT.
This evidence shows that the 6MWT can represent an individual with PAD’s functional capacity.
Interpreting results of the 6MWT can be difficult when observing a specific diseased
population. Reference equations and distances covered by healthy adults exist and can serve as a
measuring stick to determine loss in functional capacity in unhealthy adults. Enright and Sherrill
(1998) looked at almost 300 healthy adults to determine average distance covered for men and
for women. The median distance walked was 576 meters for men and 494 meters for women.
Chetta et al. (2006) found that mean distance for both genders was 614 meters. When looking at
non-healthy individuals, mean distance covered is drastically lowered, particularly in individuals
with cardiovascular disease. Bittner et al. (1993) measured patients with coronary obstructive
pulmonary disease (COPD) and found that average distance covered by participants was 374
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meters during the six minutes. Carter et al. (2003) also used the 6MWT in COPD patients and
found that average distance walked for men was 416 meters and for women was 367 meters.
These findings show that the 6MWT is an acceptable measure of functional capacity for patients
with cardiovascular disease. They also show that the presence of cardiovascular disease
decreases the overall distance covered during the 6MWT. Because of this, the 6MWT is the most
common ambulatory measure used for individuals with PAD.
The 6MWT is a staple in the PAD community for testing current functional ability as
well as declines over time. This test was adopted for these ischemic patients because walking
performance depends heavily on aerobic metabolism and the ability of said metabolism to keep
up with the energy requirements of the working muscle (Green & Askew, 2001). When PAD
patients perform the 6MWT, intermittent claudication (IC) symptoms generally appear. In some
patients, IC gets so severe that they have to take a break or cannot complete the test. For this
reason, time to onset of claudication is generally measured and recorded. These factors can be
compared as pain free walking versus non-pain free walking. The claudication scale is a scale
from 0-4 that expresses the severity of claudication symptoms being felt at a specific moment in
time. A score of “0” is indicative of no claudication pain while a score of “4” is indicative of
extremely severe pain to the point of immobilization. Upon rest, this pain generally subsides
within several minutes and the individual can continue walking.
Faucheur et al. (2008), observed that the average distance covered by 24 PAD patients
was 184 meters with a range of 144-246 meters. Interesting to note in this study, 50% of
participants had to stop at least once during the test before completing the test. Other studies
have concluded that walking performance is 40-50% less in PAD patients compared to healthy
controls (Regensteiner et al., 1993). Average time to onset of claudication in PAD patients is
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generally between 2-4 minutes (Askew, Green, Hou, & Walker, 2002; Hiatt et al., 1988;
Womack, Sieminski, Katzel, Yataco, & Gardner, 1997).
Borg Scale
Borg’s scale is a measure for assessing an individual’s rating of perceived exertion (RPE).
The borg scale is based on numerical values that represent the individual’s current exertion level
to determine exercise intensity. The scale ranges from 6-20 with “6” representing very easy work
and “20” representing the absolute maximum for how hard an individual could work (Karavatas
& Tavakol, 2005). The scale is often used at different points throughout an exercise testing
protocol to determine the perceived exertion level of the subject. The RPE scale should not be
confused with the claudication scale that measures pain; the RPE scale is a subjective tool
measuring perceived exertion and is a subjective measure of exercise intensity. Karavatas and
Tavakol (2005) examined the correlation between the RPE scale and heart rate. They found that
the correlation between the two values was .58 which was significantly different from zero.
Males were found to have a slightly higher correlation (0.60) than females (0.56). The borg scale
is often used in different submaximal and maximal exercise tests to track how hard an individual
is working. In the 6MWT, it can be used to track exertion as well as be used to determine what
exertion levels are most often correlated to the onset of claudication.
Summary
Peripheral arterial disease causes decreases in blood flow and metabolic oxidative
abnormalities that become more apparent with exertion. This pathophysiology leads to
hemodynamic changes such as the rate of blood lactate accumulation and clearance during
exercise. These variables will be observed in patients with PAD during the 6MWT and compared
to healthy controls.
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CHAPTER THREE
METHODOLOGY
The purpose of this study was to measure how the presence of peripheral arterial disease
affects resting, post-exercise, and post-recovery blood lactate during and following the 6MWT.
Participants
A total of 49 individuals (21 males and 28 females) age ≥ 50 years, both with and without
peripheral arterial disease voluntarily participated in this study (Table 1). Sixteen participants
with an ABI ≤ 0.90 made up the experimental group while 33 participants with an ABI > 0.90
made up the control group. Volunteers were recruited from the northwest Arkansas and northeast
Oklahoma areas. Health history was used to identify any immediate risks that may have been
exacerbated with exercise (Appendix A). Participants could not have uncontrolled cardiovascular
disease, diabetes, or hypertension in order to be approved to participate in this study. If the
participant was under current instruction by their doctor to not participate in physical activity,
they were excluded from the study. Other inclusion criteria included age and Montreal Cognitive
Assessment (MoCA) score; all participants were required to be over the age of 50 years old and
to have scored ≥ 26 on the MoCA.
Study Design
This study was a cross sectional design consisting of one testing day that required no
more than three hours per participant.
Pre-Testing Procedures
Participation was voluntary and a signed informed consent provided clearance and
indicated participant understanding of study protocols and risk factors associated with
participation (Appendix B). The Montreal Cognitive Assessment was given to all participants to
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ensure that they could ethically sign the informed consent. The protocol was approved by the
Institutional Review Board at the University of Arkansas, Fayetteville (Appendix C). Height and
weight of each participant was measured using a Detecto Physician’s Scale (Webb City, MO). A
health history questionnaire was used to assess and identify any immediate risks that may be
intensified with physical activity. Some of these risks included dyspnea, ischemia, heart
palpitations, and drastic blood pressure changes.
Resting Measures
Ankle-brachial index (ABI) was taken in each individual at rest before the
commencement of the 6MWT. A Portable Doppler with 8-10 MHz probe was utilized to
measure the systolic blood pressure of the brachial artery in the arms and the dorsalis pedis of the
ankles. To take the measure, the participant lie supine as the pressure cuffs were placed with the
bottom of the cuff approximately 2-3 cm above the cubital fossa on the arms and malleolus at the
ankle. The participant remained supine for 10 minutes before the measure was taken. First, the
brachial pulse was palpated to determine its precise location to obtain an audible pulse. Once the
location was confirmed, transmission gel was applied over the pulse site. The tip of the Doppler
probe was placed at a 45° angle pointed in the direction of the participant’s head until an audible
pulse signal was obtained and the pressure cuff was then inflated. The cuff was inflated 20-30
mmHg above the point where the pulse was no longer audible. From this point, the pressure cuff
was deflated at a rate of 2-3 mmHg per second while observing the manometer and reading
where the first pulse signal was heard and that value was recorded as the systolic value. Once the
systolic value was found, the pulse site was cleaned and the procedure was repeated on the other
arm. In the circumstance that a pressure needed to be repeated, at least one minute was allowed
between readings. BP was then taken using the same technique in the legs; however in the legs,
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blood pressure was taken approximately 2-3 cm proximal to the malleolus at the ankle. After the
pulse was palpated and an audible pulse was confirmed, transmission gel was applied and the
pressure was taken and recorded for each leg. The higher brachial systolic pressure was used to
calculate the ABI for both legs. One measure was taken in each arm and in each ankle.
Prior to the initiation of the 6MWT, resting lactate was measured by the standard fingerprick method. The Accutrend Lactate (Indianapolis, IN) was utilized in the participant’s nondominant hand. Accutrend Lactate analyzer uses light impulses from an LED to measure the
color produced on the lactate test strip during the reaction and then compares this to a baseline
value to easily determine lactate levels. Each participant had their own individual lancet to
ensure safety and prevent contamination. Capillary blood samples were taken from the side of
the fingertip. Three different lactate measures were taken: 1) at rest, 2) at the immediate
conclusion of the 6MWT, and 3) 20 minutes following the cessation of exercise. To take lactate
measurements, the administrator first put on gloves and cleaned the pricking site with an alcohol
swab. The lancet was then inserted into the fingertip and the first drop of blood was wiped away.
The finger was then massaged until a large drop of blood rested on the top of the wound. This
was then squeezed onto the lactate strip which was then analyzed with the Accutrend lactate to
determine the lactate level at that particular time point.
Also, prior to the initiation of the 6MWT, resting hemoglobin saturation was assessed
using the Nonin SportStat Pulse Oximeter (Plymouth, MN). This was done quickly and noninvasively by placing the device on the fingertip of the participant’s dominant hand to determine
saturation levels. This also measured the participant’s resting heart rate. Hemoglobin saturation
was also measured every minute throughout the 6MWT to ensure that saturation levels did not
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fall below 92%. If levels dropped below this mark for two consecutive minutes, the test was
ceased and the individual was asked to rest until levels read at least 92%.
6MWT
The 6MWT took place on a hard, flat surface. The course was 50 yards long marked by
cones to signify where the participant should turn and return in the opposite direction.
Participants were instructed to walk as far as possible in the allotted six minutes. Encouragement
was given in moderation to ensure that the individual was pushing themselves as far as they
could before resting or stopping. Only one trial was performed per participant.
Two scales were utilized at every 50-yard increment during the 6MWT. The Borg’s Scale
of rating of perceived exertion (RPE) was used to determine how hard the individual felt that
they were working (Appendix D). They were asked to put their overall exertion into one number
on the Borg’s scale and that number was recorded for each lap. A score of “6” on the RPE scale
was described as the exertion required to sit on a couch while a score of “20” was described as
the exertion required to work as hard as possible before immediately before failure. To determine
claudication symptoms during the 6MWT, the claudication scale was used (Appendix E).
Individuals ranked their overall claudication pain every 50 yards and onset of claudication was
marked in all participants. A “0” on the claudication scale was described as no claudication pain
at all. A “4” was described as unbearable claudication pain that required an individual to stop
exercise altogether.
Immediately following the 6MWT, HR and hemoglobin saturation were read from the
pulse oximeter and blood lactate was taken again from the participant’s same hand. The
participant was then asked to lie down for 20 minutes and lactate was taken for a third time at the
conclusion of the 20 minute recovery period.
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Variables
The dependent variables in this study were 1) total distance covered in the 6MWT and 2)
blood lactate levels. Within blood lactate levels, three specific time points were measured: a)
blood lactate at rest, b) blood lactate at the immediate conclusion of the 6MWT, and c) blood
lactate at 20 minutes post 6MWT. The independent variable assessed in this study was the
presence of PAD as defined by an individual’s ABI.
Statistical Analysis
Statistical significance was set at the α ≤ .05 level and all results are reported as means ±
standard deviations. SPSS statistical software (Armonk, New York) was utilized to analyze all
data. A repeated-measures analysis of variance was conducted to compare the effect of having
PAD on lactate concentrations at rest, post 6MWT, and 20 minutes post 6MWT.
The 6MWT total distance, rating of perceived exertion scale, claudication scale,
hemoglobin saturation, and heart rate were measured in each participant at rest and immediately
following the 6MWT in order to determine intensity. A repeated measures analysis of variance
was conducted to determine intensity between the two groups.
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CHAPTER FOUR
RESULTS
Upon analyzing blood lactate levels at all three time intervals, the data did not
demonstrate a significant statistical difference between the presence of peripheral arterial disease
and level of blood lactate. Results indicated that PAD, as classified by an individual’s ABI, did
not show lead to a significantly different amount of blood lactate in an individual at rest,
immediately following the 6MWT, or after a 20-minute rest period. Blood lactate concentrations
taken at these three time intervals appeared to follow the same pattern and values were not
statistically different between groups.
Demographics
When evaluating the demographic variables between groups, no significant differences
were found besides ABI (F[1, 47] = 48.72, p = <.0001) (Figure 1) and resting HR (F[1, 47] =
4.03, p = .05). Individuals in the PAD group had ABI values that were, on average, 20% less
than individuals in the healthy control group. Height (F[1, 47] = 2.31, p = .14), weight (F[1, 47]
= 0.00, p = .95), age (F[1, 47] = 1.39, p = .24), MoCA score (F[1, 47] = 3.23, p = .08), resting
hemoglobin saturation (F[1, 47] = 3.83, p = .57), and resting lactate (F[1, 47] = 0.82, p = .37) did
not differ between groups indicating that the groups were similar and comparable (Table 1).
Classification of Groups
Ankle Brachial Index values were taken at rest on each individual and were used to
classify an individual as PAD or Non-PAD using the 0.90 cut off. Out of 49 total participants, 33
were classified as Non-PAD with an average ABI of 1.03 ± 0.09 and 16 were classified as PAD
with an average ABI of 0.83 ± 0.09 (Figure 1).
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Hypothesis One
The primary purpose of this study was to observe how the presence of peripheral arterial
disease affects resting blood lactate and the rate of post-exercise blood lactate and post-recovery
blood lactate during and following the 6MWT. The first hypothesis stated that PAD patients
would have a higher resting blood lactate level when compared to healthy controls. A repeatedmeasures ANOVA statistical analysis was performed on each of the tested dependent variables
to determine the differences between blood lactate values at each time period (Figure 2). At rest,
there was not a significant difference between blood lactate in Non-PAD (2.93 ± 0.83 mmol/kg)
versus PAD (2.72 ± 0.58 mmol/kg). The repeated-measures ANOVA showed that there was not
a significant difference between groups (F[1, 47] = 0.86, p = .36) (Table 2). These results did not
support the hypothesis because resting blood lactate levels were not significantly different
between groups.
Hypothesis Two
The second hypothesis in this study asserted that PAD patients would have a higher
amount of blood lactate post-exercise (lactate taken immediately following 6MWT – resting
lactate) during the 6MWT when compared to healthy controls (Figure 2). Immediately following
the 6MWT, there was not a significant difference between blood lactate values in the Non-PAD
(1.35 ± 1.73 mmol/kg) vs the PAD group (1.03 ± 1.08 mmol/kg) (F[1, 47] = 0.48, p = .49)
(Table 2). These data do not support the hypothesis as there was no significant difference
between post-exercise blood lactate between PAD and Non-PAD groups.
Hypothesis Three
The third hypothesis in this study indicated that PAD patients would have a slower rate of
blood lactate clearing post-recovery (lactate taken 20 minutes post 6MWT – post-exercise
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lactate) following the 6MWT when compared to healthy controls (Figure 2). Following 20
minutes of rest after the 6MWT, there was not a significant difference between the Non-PAD (1.33 ±1.29 mmol/kg) vs. the PAD (-0.87 ± 0.94 mmol/kg) in blood lactate post-recovery (F[1,
47] = 1.62, p = 0.21) (Table 2). The PAD group had a post-recovery blood lactate of
approximately 35% lower than the Non-PAD group; however, this value was not found to be
significant by the repeated measures ANOVA statistical analysis. This hypothesis was not
supported by the data because post-recovery blood lactate between groups was not significantly
different.
Summary of Repeated-Measures ANOVA
Specifically, these results suggest that blood lactate levels at rest, post-exercise
(following 6MWT), and post-recovery (20 minutes following 6MWT) do not significantly differ
with the reduced circulation and blood flow seen in individuals with PAD compared to
individuals without PAD (Table 2, Figure 2). The repeated-measures ANOVA also demonstrates
that there was no group by time interaction between relative blood lactate concentration changes
at the time points observed between groups (Table 4).
Standardization of Intensity
During the 6MWT, a self-selected pace allowed for possible differences in intensity
variables such as overall distance covered, rating of perceived exertion (RPE) values,
claudication score (CS) values, hemoglobin saturation (HS) values, and changes in heart rate
(HR). A repeated-measures ANOVA statistical analysis was performed on each of these values
to check for differences in intensity achieved between groups (Table 3).
6MWT distance. The mean distance traveled during the 6MWT for each group was
found and compared. The Non-PAD group (606.24 ± 118.88yards) did not walk significantly
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further than the PAD group (596.06 ± 104.98yards) (Figure 3). The repeated-measures ANOVA
showed that the presence of PAD did not impact overall distance traveled (F[1, 47] = 0.08, p
= .77).
Rating of perceived exertion. The change in perceived exertion from rest to the
conclusion of the 6MWT was determined for each individual and the mean for each group was
found and compared. The Non-PAD group had a mean change of 7.76 ± 2.25 while the PAD
group had a mean change of 7.25 ± 2.02 (Figure 4). The ANOVA showed that the change in
perceived exertion following the 6MWT was independent of disease classification (F[1, 47] =
0.58, p = .45).
Claudication scale. The change in the claudication pain scale from rest to the conclusion
of the 6MWT was also determined for each participant and then the mean for each group was
determined. When comparing these means, it was found that the Non-PAD group (0.30 ± 0.77)
did not differ significantly from the PAD group (0.38 ± 0.72) (Figure 5). The repeated-measures
ANOVA showed that the change in the claudication pain scale from rest-to-conclusion of the
6MWT was not dependent on the presence of PAD (F[1, 47] = 0.10, p = .76).
Hemoglobin saturation. Hemoglobin saturation was taken at every minute during the
6MWT but changes for each participant were recorded by subtracting the value at rest from the
value at the conclusion of the 6MWT. Means were found for each group and then compared to
identify differences between groups. The Non-PAD group exhibited a mean change of -1.24 ±
2.57 while the PAD group exhibited a mean change of -1.38 ± 2.90 (Figure 6). The repeatedmeasures ANOVA again showed that the change in hemoglobin saturation during the 6MWT
was not different between groups (F[1, 47] = 0.03, p = .87).
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Heart rate. Lastly, resting heart rate was subtracted from the individual’s heart rate at the
conclusion of the 6MWT. The mean change in heart rate was calculated for each group and
compared between groups to identify any differences between change in HR during the 6MWT.
Mean change in HR for the Non-PAD group was 48.9 ± 19.6 bpm which was not significantly
different from the mean change of 44.9 ± 10.3 bpm in the PAD group (Figure 7). The repeatedmeasures ANOVA demonstrated that the change in HR from rest to the conclusion of the 6MWT
was not significant between groups (F[1, 33] = 0.39, p = .53).
Summary of Repeated-Measures ANOVA
Specifically, these results suggest that the exercise intensity achieved was not different
between groups. The repeated-measures ANOVA also demonstrates that there was no group by
time interaction between relative changes in claudication score, hemoglobin saturation, and
rating of perceived exertion (Table 5) or ankle-brachial index and heart rate (Table 6) during the
6MWT.
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CHAPTER FIVE
DISCUSSION
The primary purpose of this thesis was to investigate differences in resting blood lactate,
post-exercise blood lactate, and post-recovery blood lactate between groups. Based on the results
found during this study, the data do not indicate that there is a significant difference between
these examined variables. Several factors could be responsible for the inability of the data
collected throughout this study to demonstrate significance between groups in blood lactate
values.
First, the inclusion criteria did not exclude individuals for any medication they were
taking. It also did not exclude individuals with controlled cardiovascular disease, controlled
diabetes, cancer, and musculoskeletal injuries. All but one participant in this study had at least
one medical condition ranging from high blood pressure to cancer. Medications taken by
participants, as disclosed in the health history questionnaire, include but are not limited to
medications intended for depression, osteoporosis, allergies, thyroid disorders, arthritis,
cholesterol, diabetes, blood pressure, and long term medications taken for post-cancer and postcardiovascular event individuals. Several patients also regularly took anti-inflammatory drugs
and pain relievers for chronic joint pain or joint relief after replacement. All of these medications
play different roles in normal body functioning and can therefore cause or prevent certain
functions of the body to occur. They can also affect different aspects of the cardiovascular
system such as circulation, blood pressure, arterial compliance, and blood viscosity.
Musculoskeletal injuries were also disclosed by each participant in this study and varied from
individual to individual. These injuries included but were not limited to hip replacements, knee
replacements, bunionectomy, ankle edema, and obesity-related functional impairments. The fact
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that individuals with these different medicinal and functional issues were not excluded from
participation led to a very diverse population of participants with varying diseases, functional
limitations, and medications all of which had differing effects on walking ability and
cardiovascular function as well as perhaps even having different metabolic implications. For
example, some participants with joint-replacements complained of joint pain throughout the walk
and had a harder time completing the walk due to this pain. Others were unable to push past a
low-intensity speed without aggravating a replaced joint or other injury. In addition, without a
detailed analysis of all medications taken by participants, it is impossible to know all of the
potential effects that these medications could have had on the variables analyzed in this study.
Second, because the 6MWT has a self-selected pace, individuals were all working at
different intensities and to different points of exhaustion. While results did not show a significant
difference between groups in any of the “intensity” variables (RPE, HR, distance covered), they
did show that overall, individuals worked at a low-to-moderate intensity rather than a maximal
intensity. In both groups, the average post-exercise RPE was 13.59 ± 2.17 which is classified by
the RPE scale as “somewhat hard“ work. Based on self-report via the RPE scale, this shows that
individuals struggled to achieve maximal effort in the allotted six-minute time frame. Intensity in
older adults is defined by ACSM on a scale from 6-20 of physical exertion. They define a 12 or a
13 on this scale as moderate-intensity exercise which produces a noticeable increase in HR and
breathing and a 16 or an 17 as vigorous-intensity exercise producing a large increase in HR and
breathing (Thompson, Gordon, & Pescatello, 2010). In this study, post-exercise heart rate for
both groups following the 6MWT was 121.91 ± 16.18 bpm. For their average age (64.82 years),
based on target heart rates, they were performing work at approximately 75% of their HR max
which is defined as a moderate intensity. This again shows that individuals were not at maximal
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effort during the six-minute test (Tanaka, Monahan, & Seals, 2001). Perhaps a walk-toexhaustion test that allowed each individual to achieve maximal exertion would yield significant
results rather than a timed test where most individuals did not make it past a moderate intensity.
However, despite participants not achieving high intensity during the 6MWT, Brass et al.
(2004) showed that lactate accumulates in the muscles of individuals with PAD at rest and at
low-to-moderate workloads. He suggest that this elevated lactate in muscle is due to pyruvate
being shunted from total oxidation towards lactate production because of a dramatically different
metabolic milieu seen in PAD individuals versus healthy controls. Brass et al. found that lactate
can build up in the muscle at rest and at low workloads; however, in contrast, when looking at
lactate in the blood, the present study did not find a significantly higher amount of lactate at rest
and low intensities in individuals with PAD.
Because the 6MWT is only six minutes, perhaps blood lactate differences would be more
apparent and statistically significant during longer exercise bouts where higher intensities are
achieved. Urhausen and Kindermann (1992) examined blood lactate concentrations at different
exercise intensities and found that, in healthy adults, blood lactate only increased at high
intensities near an individual’s anaerobic threshold. It is commonly taught that higher intensity
exercise leads to a greater lactate production than lower intensity exercises (McArdle, Katch, &
Katch, 2010). Because the 6MWT is technically a “maximal” test, it can be inferred that it would
be a high intensity exercise resulting in large amounts of blood lactate build-up. However,
according to our results, most participants only performed at a low-to-moderate intensity even
when instructed to walk at maximal pace. Therefore, because high intensities were not achieved
during the 6MWT, blood lactate levels would not be expected to be elevated drastically higher
than resting levels.
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Third, because severity of PAD was not considered, nor was the presence of claudication
symptoms, it could be possible that mild-to-moderately blocked femoral arteries in individuals
(with no claudication pain) do not exhibit excessive blood lactate accumulation or prolonged
clearance time whereas individuals with severely blocked arteries (with present claudication
pain) would exhibit a stronger difference with blood lactate abnormalities compared to agematched controls. Because there is a correlation between the severity of vessel occlusion,
abnormal metabolic milieu in the muscles of individuals with PAD, and exercise impairment, it
is known that with less-severe occlusion, there would be less-severe substrate build-up (Brass,
Hiatt, & Green, 2004). It is known that with more occluded vessels, less blood flow is able to
travel to working muscle. This decreased blood flow and consequential ischemia is directly
responsible for metabolic abnormalities and substrate build-up in healthy individuals (Robbins et
al., 2011 & Hiatt et al., 1992). It can be asserted that in an individual with occluded blood flow to
one or both legs that the extent to which the vessel is occluded would play a part in the extent to
which metabolic abnormalities are present and therefore the abnormalities in substrate build-up
(Robbins et al., 2011, Hiatt et al., 1992, & McDermott et al., 1999). Because the mean ABI for
participants in the PAD group was 0.83 ± 0.09, most participants in this study fell in the “mild
blockage” category for PAD implying that they did not have extremely occluded vessels with
drastic reductions in blood flow. Because most of the PAD group did have such mild PAD and
close-to-normal blood flow and there was no statistical difference between groups in resting,
post-exercise, and post-recovery blood lactate, perhaps a more drastic experimental group is
needed to see if these variables become significant with more occluded vessels and more
inhibited blood flow.
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Last, this study classified participants as PAD based on either limb scoring an ABI of less
than or equal to 0.90. Because of this classification, only 3 of the 49 participants enrolled in this
study exhibited vessel occlusion in both limbs. All other PAD subjects had only one limb with an
ABI ≤ 0.90. In studies that have used muscle biopsies to determine enzyme and substrate
differences with PAD, the contralateral “healthy” limb is often used as its own control for the
“diseased” limb with vessel occlusion. It has been found that the activity, as well as expression,
of mitochondrial enzymes is increased only in the limb with PAD and these changes are not
observed in the healthy limb (Jansson, Johansson, Sylven, & Kaijser, 1988). Because blood
lactate is representative of lactate in the entire body and not just the affected limb, analysis of
lactate from a muscle biopsy would be a much more effective and accurate way to determine
differences in substrate build-up with PAD.
In regards to 6MWT distance, interestingly, this study did not show a significantly
different distance covered between groups as often found in other research. Chetta et al. (2006)
found that healthy adults typically walk between 450-700 yards during the 6MWT. Conversely,
Regensteiner et al. (1993) found that PAD individuals walk an average of 250-400 yards.
However, in this study, there was no significant difference between groups and the average
distance for Non-PAD (606.24 ± 118.88) and PAD (596.06 ±104.98) fell comfortably into
Chetta et al.’s range for healthy classification (450-700 yards).
Although results for the study failed to demonstrate a significant difference between the
presence of PAD in an individual and blood lactate at rest, post-exercise, and post-recovery, it is
important to note that peripheral arterial disease still impacts blood flow to working muscle and
may still have an effect on these variables under different exercise or functional conditions.
McDermott et al. (2004) showed that lower ABI values were associated with annual decline in
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6MWT time. They also showed that individuals with PAD had greater annual 6MWT time
decreases than individuals without PAD. Regensteiner et al. (1993) showed that individuals with
PAD and intermittent claudication had an approximate 50% reduction in walking performance
when compared to healthy individuals of the same age. Blood flow is often singled out as the
main cause of this reduction in functional ability and exercise capacity. Therefore, because a
large portion of the experimental population in this study did not have drastically reduced blood
flow (as inferred from their ABI), perhaps these results would be more significant if the
population had more drastic occlusion and thereby a significant decrease in blood flow that
would lead to the previously observed functional impairment.
With vessel occlusion, blood flow decreases to a greater degree along with vessel
conductance, compliance, and oxygen kinetics than in healthy individuals. Blood flow in
individuals with claudication symptoms has been found to decrease by almost 50% when
compared to healthy controls during exercise (Pernow et al., 1975). This decrease in blood flow
as a result of femoral vessel occlusion has significant implications on skeletal muscle
contractility as well as metabolite production in individuals with peripheral arterial disease.
Brass et al. (2004) showed that lactate accumulates in the muscles of individuals with PAD at
rest and at low-to-moderate workloads. This shows that the ischemic nature of blood flow in
individuals with PAD can lead to a more-than-normal blood lactate accumulation at all work
loads.
Many studies concur that exercise blood flow is markedly decreased in individuals with
PAD when compared to healthy individuals (Pernow et al., 1975). Decreased blood flow to a
working muscle leads to reduced nutrient delivery, ischemia, and impaired metabolite clearance.
These physiological changes are important because they often define functional capacity. As
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individuals with PAD age, the energy requirements for most daily tasks exceeds that of their
energy capacity due to these functional limitations. This impacts individuals as they try to
perform simple tasks in every-day life and are unable to do so without taking a break or reaching
exhaustion (Oka et al., 2003; Garg et al., 2006). Ischemia is also very important because with
recurring ischemia, muscle and tissue damage can occur. All of this information in conjunction
would infer that there would be a significant difference between femoral vessel occlusion,
decreases in exercise blood flow, and blood lactate abnormalities between PAD and Non-PAD
individuals. However, data between groups during the 6MWT was not found to be significantly
different in this study.
Conclusion
Although no difference was observed between blood lactate levels between groups, it is
important to note that physiologically, PAD elicits exercise metabolic abnormalities and
therefore a relationship may still exist between these two variables at different intensities,
durations, or exercise modes.
Future research in this area should include different functional tests than the 6MWT to
determine if a walk-to-exhaustion or a timed, set-pace exercise protocol would elicit blood
lactate differences between individuals with PAD and without PAD. Additional research could
also control for PAD severity by breaking down the population into severe PAD, moderate PAD,
mild PAD, and non-PAD groups rather than just PAD and non-PAD.
With the conclusion of this research project, it is important to continue the promotion of
walking and functional training in aging individuals whether they have decreased circulation to
their legs or not. This training can improve and prevent occluded vessels in aging adults as well
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as improve vessel compliance and blood pressure regulation. It also allows an adult to maintain
their functional capacity as they age.
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Table 1
Demographic differences between height, weight, age, MoCA score, resting ABI, resting HS,
resting HR, resting lactate, and 6MWT distance
Non-PAD

PAD

F

p

Height (cm)

166.80 ± 7.14

169.88 ± 8.05

2.31

.14

Weight (kg)

81.94± 21.36

78.13 ± 16.73

0.00

.95

Age (years)

63.67 ± 8.34

67.19 ± 9.75

1.39

.24

MoCA

28.09 ± 1.42

27.31 ± 1.08

3.23

.08

Resting ABI*

1.03 ± 0.09

0.83 ± 0.09

48.72

<.0001

Resting HS (%)

96.64 ± 1.65

97.50 ± 1.46

3.83

.57

Resting HR* (bpm)

76.09 ± 13.29

67.88 ± 10.74

4.03

.05

2.93 ± 0.83

2.71 ± 0.58

0.82

.37

605.97 ± 120.77

596.06 ± 104.98

0.08

.78

Resting Lactate
(mmol/kg)
6MWT Distance (yards)

Note. MoCA = Montreal Cognitive Assessment, ABI = ankle-brachial index, HS = hemoglobin
saturation, HR = heart rate, 6MWT = six-minute walk test. No statistical difference in measured
factors between individuals with (PAD) and individuals without (Non-PAD) peripheral arterial
disease. Values are means ± sd. *Indicates significant difference between Non-PAD and PAD
scores, p < .05
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Table 2
ANOVA analysis. Differences in blood lactate at rest, post-exercise, and post-recovery during
the six-minute walk test (6MWT).
Non-PAD

PAD

F

p

Resting Lactate (mmol/L)

2.93 ± 0.83

2.72 ± 0.58

.86

.36

Post-Exercise (mmol/L)

1.35 ± 1.73

1.03 ± 1.08

.48

.49

Post-Recovery (mmol/L)

-1.33 ± 1.29

-0.87 ± 0.94

1.62

.21

Note. No statistical difference in measured factors between individuals with (PAD) and
individuals without (Non-PAD) peripheral arterial disease. Values are means ± sd. *Indicates
significant difference between Non-PAD and PAD scores, p < .05
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Table 3
ANOVA analysis: Differences in 6MWT distance, RPE, CS, HS, and HR
Non-PAD

PAD

F

p

606.24 ± 118.88

596.06 ±104.98

0.08

.77

Change in RPE

7.76 ± 2.25

7.25 ± 2.02

0.58

.45

Change in CS

0.30 ± 0.77

0.38 ± 0.72

0.10

.76

Change in HS (%)

-1.24 ± 2.57

-1.38 ± 2.90

0.03

.87

48.88 ± 19.64

44.91 ± 10.25

0.39

.54

6MWT Distance (yards)

Change in HR (bpm)

Note. 6MWT = six-minute walk test, RPE = rating of perceived exertion, CS = claudication
scale, HS = hemoglobin saturation, HR = heart rate. No statistical difference in measured factors
between individuals with (PAD) and individuals without (Non-PAD) peripheral arterial disease.
Values are means ± sd. *Indicates significant difference between Non-PAD and PAD scores, p <
.05
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Table 4
Repeated measures ANOVA analysis. Group by time interaction between blood lactate at rest,
post-exercise, and post-recovery during the six-minute walk test (6MWT).
Source

DF

SS

MS

F

p

Time

2

37.85

18.92

23.28

.00

Time * PAD

2

1.23

0.61

.75

.47

Error (Time)

94

76.40

0.81

Note. No group by time interaction was found between the PAD group versus the Non-PAD
group when looking at blood lactate values over time (n=49).

50
Table 5
Repeated measures ANOVA analysis. Group by time interaction between Claudication Scale,
Hemoglobin saturation, and Rating of Perceived Exertion throughout the six-minute walk test
(6MWT).
Source

DF

SS

MS

F

p

CS

6

3.65

0.608

4.67

0.00

HS

6

97.93

16.32

6.04

0.00

RPE

6

935.68

155.95

125.02

0.00

CS

6

0.29

0.05

0.38

0.89

HS

6

11.99

2.00

0.74

0.62

RPE

6

3.28

0.55

0.44

0.85

CS

174

22.64

0.13

HS

174

469.89

2.70

RPE

174

217.05

1.25

Time

Time * PAD

Error (Time)

Note. No group by time interaction was found between the PAD group versus the Non-PAD
group when looking at CS (claudication score), HS (hemoglobin saturation), and RPE (rating of
perceived exertion) throughout the 6MWT (n=49).

51
Table 6
Repeated measures ANOVA analysis. Group by time interaction for ankle-brachial index and
heart rate at rest and post-exercise following the six-minute walk test (6MWT).
Source

DF

SS

MS

F

p

Time
ABI

1

0.01

0.01

0.81

.38

HR

1

33171.43

33171.43

220.66

.00

ABI

1

0.07

0.07

6.40

.02

HR

1

59.32

59.32

0.40

.53

ABI

33

0.36

0.01

HR

33

4960.77

150.33

Time * PAD

Error (Time)

Note. No group by time interaction was found between the PAD group versus the Non-PAD
group when looking at ABI (ankle-brachial index) and HR (heart rate) throughout the 6MWT
(n=49).
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Ankle Brachial Index

Ankle Brachial Index (ABI)

1.4
1.2
1
0.8
0.6

Non-PAD
PAD

0.4
0.2
0

Figure 1 ABI distribution
Note. ABI = ankle-brachial
brachial index. This figure illustrates the distribution of individuals with PAD
( ) and without PAD ( ) in terms of their ABI ((n = 49).
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Blood Lactate Levels
Blood Lactate (mmol/kg)

5

4

Non-PAD

3

PAD
2

1

Resting

Post-exercise Post-recovery

Figure 2 Blood lactate at rest, post-exercise, and post-recovery during the six-minute walk test
Note. This figure illustrates there is no statistical difference in blood lactate levels at any stage
between individuals with PAD (− −) and individuals without PAD (−) (n = 49).
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6MWT Distance

Distance (yards)

700
650
600
550
500
450
400
Distance

Non-PAD
606.24

PAD
596.06

Figure 3 Differences in 6MWT distance
Note. 6MWT = six-minute walk test. This figure illustrates there is no statistical difference in the
overall distance covered between individuals with (PAD) peripheral arterial disease and
individuals without (Non-PAD). (n = 49)
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Rating of Perceived Exertion
20

RPE Score

18
16
14

Non-PAD

12

PAD

10
8
6
Pre 6MWT

Post 6MWT

Figure 4 RPE during the 6MWT
Note: RPE = rating of perceived exertion, 6MWT = Six-Minute Walk Test. Figure illustrates
there is no statistical difference in the changes in RPE between individuals with (PAD)
peripheral arterial disease and individuals without (Non-PAD) (n = 49).
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Claudication Scale

Claudication Score

0.60
0.50
0.40
Non-PAD

0.30

PAD

0.20
0.10
0.00
Pre 6MWT

Post 6MWT

Figure 5 CS score during the 6MWT
Note. CS = Claudication Scale, 6MWT = six-minute walk test. This figure illustrates there is no
statistical difference in the changes in the CS score between individuals with (PAD) peripheral
arterial disease and individuals without (Non-PAD) (n = 49).
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Hemoglobin saturation (%)

Hemoglobin Saturation
98
98
97
97
96
96
95
95
94
94
93

Non-PAD
PAD

Pre
6MWT

Post
6MWT

Figure 6 HS during the 6MWT
Note. HS = Hemoglobin saturation, 6MWT = six-minute walk test. HS is written in terms of a
percent. This figure illustrates there is no statistical difference in the changes in HS between
individuals with (PAD) peripheral arterial disease and individuals without (Non-PAD). (n = 49)
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Heart rate (bpm)

Heart Rate
160
150
140
130
120
110
100
90
80
70
60

Non-PAD
PAD

Pre 6MWT

Post 6MWT

Figure 7 HR during the 6MWT
Note. HR = heart rate, 6MWT = six-minute walk test. This figure illustrates there is no statistical
difference in the changes in HR between individuals with (PAD) peripheral arterial disease and
individuals without (Non-PAD). (n = 35)
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APPENDIX A
Health History Questionnaire
Please answer the following questions.
Date of Birth

Today’s Date: ____________
What is your current age?

(3) No diagnosis of unstable or unmanaged cardiovascular disease, hypertension;
Have you ever had any of the following conditions? Check yes or no. If yes, explain.
Heart Disease
 Yes  No
Heart Attack

 Yes  No

Angina (Chest Pain)

 Yes  No

Peripheral Artery Disease

 Yes  No

Stroke

 Yes  No

High Cholesterol (>220)

 Yes  No

High Blood Pressure (>140/90)

 Yes  No

Diabetes

 Yes  No

Rheumatic Fever

 Yes  No

Aneurysm

 Yes  No

No history of hospitalization within the past year that would prohibit physical activity
Have you ever had any of the following conditions? Check yes or no. If yes, explain.
Severe Illness (in the last year)
 Yes  No
Operations (in the last year)

 Yes  No

Broken bone/fracture (in the last year)

 Yes  No

History of a fall within the preceding one year
Have you fallen in the past 12 months?

 Yes  No

If yes, explain.

67
Additional information
Have you experienced any of these symptoms? Check yes or no.
explain.
Pain and/or discomfort in the chest, neck, jaw, or arms
 Yes  No
Shortness of breath at rest or with mild exertion

 Yes  No

Dizziness

 Yes  No

Ankle edema (swelling)

 Yes  No

Rapid or irregular beating heart

 Yes  No

Leg pain, cramping, or tightness during exercise

 Yes  No

Heart murmur

 Yes  No

Fatigue or shortness of breath during the day

 Yes  No

Do you smoke?

 Yes  No

If yes,

 Quit

(8) Please attach a list of all medication (prescription or over-the-counter) you are currently
taking or use the form below.
Medication

Reason Prescribed

When do you take this medication?
(check all that apply)
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
 Morning  Mid-Day  Evening  Bedtime
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APPENDIX B
INFORMED CONSENT
Title: Peripheral arterial disease, balance, sensation, muscle activity, function, lactate levels, and
ankle brachial index measures.
Investigator(s):
Jennifer Vincenzo
HPER
University of Arkansas
155 Stadium Drive-HPER 321Q
Fayetteville, AR 72701
479-575-2975
jvincenz@uark.edu

Michelle Gray
HPER
University of Arkansas
155 Stadium Drive-HPER
Fayetteville, AR 72701
479-575-2975
rgray@uark.edu

Rebecca Roderick
HPER
University of Arkansas
155 Stadium Drive – HPER
Fayetteville, AR 72701
479-575-2975
rroderic@uark.edu

Description: You are being asked to participate in a research study. The purpose of this research
study is to determine the relationship between physical measurements (such as leg muscle
activity, balance, sensation, and mobility), blood lactate levels, and peripheral arterial disease.
You will complete a series of assessments in one day. It is expected these assessments will take
less than three hours of your time. You will be asked questions to assess your thinking ability,
your age, and medical history. Your height and weight will be taken on a scale. Your blood
pressure in your arm and leg will be measured to determine how your blood flow is. Your
sensation will be assessed for your feeling of pressure on the bottom of your feet. Your balance
will be measured on a standing machine called the Biodex Balance System. Your muscle activity
during all these tests will be measured by surface electrodes that are placed on your legs during
the balance testing. You will also perform standing up, standing in place, and walking tests.
During one of the walking tests, you will walk across a flat mat on the floor to assess your
walking. There will be rest breaks as needed. There will be a trained clinician with you at all
times. You may choose to stop the testing at any time if you feel that you have reached a level in
which you can no longer continue. Four small blood samples will be taken from your fingertips
at different time points during the 6 minute walk test. You may choose to not participate in this
portion of the study. Any information you possess about your health status or previous
experiences of unusual feelings with physical activity may affect the safety and value of your
testing. You are responsible to fully disclose such information when requested to the testing
staff. All testing will be designed by trained personnel and monitored throughout the course of
the study.
Risks and Benefits: There is no compensation for participating in this study. There exists the
possibility of certain changes occurring during the assessments. They include, but are not
limited to, muscle or joint injury, possible dizziness and predisposition to injury, and falls. There
is a risk of pain and contamination with the finger prick test. Trained personnel will be available
and with you during testing at all times in the event an unforeseen instance may arise. The
results obtained will assist in the assessment and prevention of falls and balance deficits in
individuals with peripheral arterial disease.
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Voluntary Participation: Permission for you to engage in the testing is voluntary. You are free
to deny or withdraw from testing at any time, if you so desire.
Confidentiality: All information collected will be kept confidential to the extent allowed by law
and University policy. Test results will be kept in a secure location (HPER 309). After initial
contact with the primary investigator, a code number (e.g. 100,101, etc) will be assigned to you.
All data collection sheets and electronic data files will only have the code number to identify
you.
Right to Withdraw: You are free to refuse to participate and to withdraw at any time. Your
decision to withdraw will bring no penalty to you.
Questions: If you have questions or concerns about this study, you may contact Jennifer
Vincenzo or Dr. Michelle Gray at (479) 575-2975 or by e-mail at jvincenz@uark.edu. For
questions or concerns about your rights as a research participant, please contact Ro Windwalker,
the University’s IRB Coordinator, at (479) 575-2208 or by e-mail at irb@uark.edu.
Informed Consent: I, ____________________________________________, have read the
description of this program, including the purpose of the program, the procedures to be used, the
potential risks and side effects, the confidentiality, as well as the option to withdraw from the
program at any time. The investigator has explained each of these items to me.
My signature below indicates that I freely agree to participate in this study and that I have
received a copy of this agreement from the investigator. I understand that participation in all
activities related to this project is voluntary on behalf of all participants. The university makes no
commitment to provide free medical care or payment for any unfavorable outcomes resulting
from participation in this research.
Participant:_____________________________________________________
Date:___________________
Witness:_______________________________________________________
Date:____________
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APPENDIX C
September 28, 2012
MEMORANDUM
TO:

Jennifer Vincenzo
Rebecca Roderick
Michelle Gray

FROM:

Ro Windwalker
IRB Coordinator

RE:

New Protocol Approval

IRB Protocol #:

12-09-076

Protocol Title:

Physical and Functional Assessment of Individuals with Peripheral
Arterial Disease Compared to Individuals without Peripheral
Arterial Disease

Review Type:
Approved Project Period:

EXEMPT

EXPEDITED

FULL IRB

Start Date: 09/28/2012 Expiration Date: 09/27/2013

Your protocol has been approved by the IRB. Protocols are approved for a maximum period of
one year. If you wish to continue the project past the approved project period (see above), you
must submit a request, using the form Continuing Review for IRB Approved Projects, prior to the
expiration date. This form is available from the IRB Coordinator or on the Research Compliance
website (http://vpred.uark.edu/210.php). As a courtesy, you will be sent a reminder two months
in advance of that date. However, failure to receive a reminder does not negate your obligation
to make the request in sufficient time for review and approval. Federal regulations prohibit
retroactive approval of continuation. Failure to receive approval to continue the project prior to
the expiration date will result in Termination of the protocol approval. The IRB Coordinator can
give you guidance on submission times.
This protocol has been approved for 40 participants. If you wish to make any modifications
in the approved protocol, including enrolling more than this number, you must seek approval
prior to implementing those changes. All modifications should be requested in writing (email is
acceptable) and must provide sufficient detail to assess the impact of the change.
If you have questions or need any assistance from the IRB, please contact me at 210
Administration Building, 5-2208, or irb@uark.edu.
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January 17, 2013
MEMORANDUM
TO:

Jennifer Vincenzo
Rebecca Roderick
Michelle Gray

FROM:

Ro Windwalker
IRB Coordinator

RE:

PROJECT MODIFICATION

IRB Protocol #:

12-09-076

Protocol Title:

Physical and Functional Assessment of Individuals with Peripheral
Arterial Disease Compared to Individuals without Peripheral
Arterial Disease

Review Type:
Approved Project Period:

EXEMPT

EXPEDITED

FULL IRB

Start Date: 01/15/2013 Expiration Date: 09/27/2013

Your request to modify the referenced protocol has been approved by the IRB. This protocol is
currently approved for 80 total participants. If you wish to make any further modifications in
the approved protocol, including enrolling more than this number, you must seek approval prior
to implementing those changes. All modifications should be requested in writing (email is
acceptable) and must provide sufficient detail to assess the impact of the change.
Please note that this approval does not extend the Approved Project Period. Should you wish to
extend your project beyond the current expiration date, you must submit a request for
continuation using the UAF IRB form “Continuing Review for IRB Approved Projects.” The
request should be sent to the IRB Coordinator, 210 Administration.
For protocols requiring FULL IRB review, please submit your request at least one month prior to
the current expiration date. (High-risk protocols may require even more time for approval.) For
protocols requiring an EXPEDITED or EXEMPT review, submit your request at least two weeks
prior to the current expiration date. Failure to obtain approval for a continuation on or prior to
the currently approved expiration date will result in termination of the protocol and you will be
required to submit a new protocol to the IRB before continuing the project. Data collected past
the protocol expiration date may need to be eliminated from the dataset should you wish to
publish. Only data collected under a currently approved protocol can be certified by the IRB for
any purpose.
If you have questions or need any assistance from the IRB, please contact me at 210
Administration Building, 5-2208, or irb@uark.edu.
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April 10, 2013
MEMORANDUM
TO:

Jennifer Vincenzo
Rebecca Roderick
Michelle Gray

FROM:

Ro Windwalker
IRB Coordinator

RE:

PROJECT MODIFICATION

IRB Protocol #:

12-09-076

Protocol Title:

Physical and Functional Assessment of Individuals with Peripheral
Arterial Disease Compared to Individuals without Peripheral
Arterial Disease

Review Type:
Approved Project Period:

EXEMPT

EXPEDITED

FULL IRB

Start Date: 04/08/2013 Expiration Date: 09/27/2013

Your request to modify the referenced protocol has been approved by the IRB. This protocol is
currently approved for 80 total participants. If you wish to make any further modifications in
the approved protocol, including enrolling more than this number, you must seek approval prior
to implementing those changes. All modifications should be requested in writing (email is
acceptable) and must provide sufficient detail to assess the impact of the change.
Please note that this approval does not extend the Approved Project Period. Should you wish to
extend your project beyond the current expiration date, you must submit a request for
continuation using the UAF IRB form “Continuing Review for IRB Approved Projects.” The
request should be sent to the IRB Coordinator, 210 Administration.
For protocols requiring FULL IRB review, please submit your request at least one month prior to
the current expiration date. (High-risk protocols may require even more time for approval.) For
protocols requiring an EXPEDITED or EXEMPT review, submit your request at least two weeks
prior to the current expiration date. Failure to obtain approval for a continuation on or prior to
the currently approved expiration date will result in termination of the protocol and you will be
required to submit a new protocol to the IRB before continuing the project. Data collected past
the protocol expiration date may need to be eliminated from the dataset should you wish to
publish. Only data collected under a currently approved protocol can be certified by the IRB for
any purpose.
If you have questions or need any assistance from the IRB, please contact me at 210
Administration Building, 5-2208, or irb@uark.edu.
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APPENDIX D
Rate of Perceived Exertion
6

NO EXERTION AT ALL

7
8

EXTREMELY LIGHT

9
10

VERY LIGHT

11

LIGHT

12
13

SOMEWHAT HARD

14
15

HARD (HEAVY)

16
17

VERY HARD

18
19

EXTREMELY HARD

20

MAXIMAL EXERTION
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APPENDIX E
Claudication Scale
0

No claudication symptoms or discomfort

1

Mild discomfort or pain

2

Moderate discomfort or pain

3

Intense pain from which you cannot be
distracted

4

Unbearable pain—you must stop

